Atara Biotherapeutics hires ex-Genentech SVP to lead its global R&D program
Atara Biotherapeutics recently hired Dietmar Berger, M.D., Ph.D., as its R&D global head. During the time in Genentech, Berger was involved in the approval of several drugs including the PD-L1 checkpoint inhibitor Tecentriq. Berger was hired by Genentech late in 2011 to supervise HER2 breast cancer programs, later he was promoted to the position of SVP global clinical development for oncology and hematology group.
Minor effects of multiple genes collectively determine migraine risk
A group of scientists studied data of more than 1,500 families in Finland to examine two conflicting theor...
